News

TAIPEI & SHANGHAI (January 27, 2026) — Exonox Biosciences, Inc., a leader in precision biotechnology R&D, announced today the signing of a “Dual-Brand Strategic Cooperation Agreement” with SQLab (Shanghai). The initial phase of this partnership focuses on chronic kidney disease (CKD)—a high-incidence condition in cats—with the launch of a “Feline Early Kidney Disease Rapid Test Kit” developed by Exonox Biosciences. This product will be distributed through SQLab’s network and the thousands of animal hospitals under the 新瑞鵬 (New Ruipeng) Pet Healthcare Group, China’s leading pet medical provider, to capture the massive pet wellness market.

Core Breakthrough: From Proteomics R&D to Clinical POCT

The core product of this collaboration stems from Exonox Biosciences’ advanced proteomics R&D platform. Highly sensitive protein biomarkers discovered in the lab have been successfully transformed into a practical urine-based rapid test for veterinary clinical use. This rapid test overcomes the limitations of traditional diagnostics through four key advantages:

• Early Screening: Detects abnormal indicators during the initial stages of renal impairment, allowing veterinarians to seize the “golden window” for treatment.
• Non-Invasive Sampling: Requires only a single drop of urine, significantly reducing the stress and discomfort cats experience during blood draws.
• Speed and Convenience: Features a simple testing process that yields results within minutes.
• Point-of-Care Testing (POCT): Enables veterinarians to interpret results on-site during consultations and immediately develop follow-up care plans.

Strategic Alliance: Accessing Thousands of Hospital Channels

The partner, SQLab, is a 100% owned subsidiary of the New Ruipeng Pet Healthcare Group, the largest pet medical system in China. New Ruipeng operates thousands of animal hospitals across the country, possessing vast clinical data and significant market influence.

Yuan-Ting Lo, General Manager of SQLab, stated: “SQLab is committed to introducing diagnostic technologies with the highest clinical value. With nearly 100 million cats in China, Exonox’s ability to translate proteomics R&D into products—combined with our clinical data and channel advantages—will fill the current market gap in early feline kidney disease screening and help define new standards for pet healthcare”.

Dr. Kenner Wang, Chairman and CEO of Exonox Biosciences, added: “We have successfully turned complex laboratory research into a commercially viable clinical tool. Through this tight-knit alliance with SQLab and the New Ruipeng Group, we are not only rapidly entering the Chinese market but also bringing the philosophy of ‘non-invasive, real-time, and precise’ testing into the daily care of beloved pets”.

Future Outlook: Deepening the Precision Medicine Ecosystem

This agreement marks the official expansion of Exonox Biosciences’ commercial footprint in China. Moving forward, the company will continue to leverage its proteomics and bioanalytical platforms to develop a diverse range of POCT products for chronic diseases and precision preventive medicine, driving the technological transformation of the pet healthcare industry alongside SQLab.

About Exonox Biosciences, Inc.

Exonox Biosciences focuses on proteomics R&D and clinical translation, featuring high-end mass spectrometry analysis and biomarker development capabilities. The company is dedicated to transforming cutting-edge laboratory results into high-performance early detection solutions, providing scientific evidence-based support for both human and pet precision medicine.

About SQLab and New Ruipeng Group

SQLab (Shanghai) is a 100% subsidiary of China’s New Ruipeng Pet Healthcare Group. Its SQ Reference Laboratory is a leader in pet medical testing, clinical research, and academic promotion. New Ruipeng Pet Healthcare Group is the titan of China’s pet medical industry, owning thousands of hospitals and digital platforms nationwide, dedicated to building a world-class pet health service ecosystem.